Back to Research Home
EWEdwards Lifesciences Corp
Health Care · Health Care Equipment · Large
$89.07−1.13%
As of 23 Oct 2026Mkt cap $52.3B
Stage 13
AVOID
Fundamentals
38.2/75
Technical
9.7/15
Independent
47.9/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +3.9%
- 3M
- +7.3%
- 6M
- +5.8%
- 1Y
- +15.9%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 51.2xHist median 18.6x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 36.4x
- FCF yield
- 2.7%
Quality
- ROIC
- 13.3%
- Operating margin
- 25.3%
- FCF margin
- 22.0%
- Current ratio
- 3.7x
Growth
- Revenue growth
- +11.5%Latest FY YoY
- Revenue CAGR
- +3.8%
- EPS CAGR
- −6.4%
- FCF CAGR
- −1.3%
Capital
- Share-count trend
- −2.0%3Y annualised
- Net cash
- $2.2B-1.4x OCF
Annual trend
- CAGR 2021–2025
- +3.8%
- Latest · 2025
- $6B
- YoY
- +11.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-04
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- early-recovery
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded